Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | VRNA | Ordinary Shares | Award | $0 | +200K | +7.95% | $0.00 | 2.72M | Aug 7, 2024 | Direct | F1, F2 |
transaction | VRNA | Ordinary Shares | Tax liability | -$230K | -87.9K | -3.24% | $2.62 | 2.63M | Aug 7, 2024 | Direct | F1, F3, F4, F5 |
Id | Content |
---|---|
F1 | Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. |
F2 | Represents an award of Ordinary Shares upon vesting of Performance Restricted Share Units in connection with the Issuer's first commercial sale of ensifentrine. |
F3 | Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of the Performance Restricted Share Units described in footnote 2 above. |
F4 | The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on August 6, 2024 divided by eight (8). |
F5 | Consists of (i) 635,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 79,375 ADSs); and (ii) 1,992,416 Ordinary Shares underlying 249,052 ADSs. |